In short: Named once, as the fix for the capacity problem that cost Novo its lead: alongside "DKK 47.2 billion in 2024 to expand factories," Novo "acquired three manufacturing sites from Catalent for $11 billion." The result is dated — "as of early 2025, the FDA declared the shortage resolved." No view on Catalent, which is no longer independently listed.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.